Open AccessModulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: Implications for cancer therapy
Author(s) -
Vijay Kumar Kalia,
S Prabhakara,
Vidya Narayanan
Publication year - 2009
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.55145
Subject(s) - glioma , micronucleus test , viability assay , cancer cell , trypan blue , glycolysis , hela , biology , cell culture , dna damage , cancer research , cell growth , dna repair , hexokinase , radiosensitivity , cell , chemistry , microbiology and biotechnology , biochemistry , cancer , radiation therapy , medicine , metabolism , toxicity , dna , genetics , organic chemistry
2-Deoxy-D-glucose (2-DG), a glycolytic inhibitor, was observed earlier to increase DNA, chromosomal, and cellular damage in tumor cells, by inhibiting energy-dependent repair processes. Lonidamine (LND) selectively inhibits glycolysis in cancer cells. It damages the condensed mitochondria in these cells, impairing thereby the activity of hexokinase (predominantly attached to the outer mitochondrial membranes). It inhibits repair of radiation-induced potentially lethal cellular damage in HeLa and Chinese hamster (HA-1) cells. However, other than a preliminary study on human glioma (BMG-1) cells in this laboratory, the effects of LND on radiation-induced cytogenetic damage have not been reported earlier.